Chinese firm seeks European trials for Alzheimer’s drug

A newly approved Chinese drug for Alzheimer’s will start clinical trials in Europe and the US next year as the country’s first novel therapy for the incurable disease seeks global legitimacy.

Shanghai Green Valley Pharmaceutical plans to recruit around 2,046 patients with mild-to-moderate Alzheimer’s for trials at 200 sites across Europe, North America, and Asia Pacific for 18 months, according to the company’s vice president, Li Jinhe.